Poolbeg Pharma (LON:POLB) Stock Price Down 7.2% – Should You Sell?

Poolbeg Pharma PLC (LON:POLB – Get Free Report)’s share price dropped 7.2% during mid-day trading on Wednesday . The company traded as low as GBX 7.37 ($0.10) and last traded at GBX 7.70 ($0.10). Approximately 2,541,886 shares changed hands during mid-day trading, an increase of 44% from the average daily volume of 1,765,747 shares. The stock had previously closed at GBX 8.30 ($0.11).

Poolbeg Pharma Trading Up 8.1 %

The company’s 50 day moving average price is GBX 10.87 and its 200-day moving average price is GBX 11.84. The company has a market capitalization of £40 million, a PE ratio of -800.00 and a beta of 2.11.

Poolbeg Pharma Company Profile

(Get Free Report)

Poolbeg Pharma plc operates as a biopharmaceutical company in the United Kingdom. It develops POLB 001, a p38 MAP Kinase inhibitor for the treatment of severe influenza; POLB 002, an in­licensed first­in­class broad spectrum RNA­based immunotherapy for respiratory virus infections; and POLB 003, an intramuscular vaccine to prevent Melioidosis.

See Also

• Five stocks we like better than Poolbeg Pharma
• The Significance of Brokerage Rankings in Stock Selection
• 3 Micro-Caps Set for Major Moves: Balancing Risk and Opportunity
• Investing in Travel Stocks Benefits
• Autodesk Named a “Top Pick” by Morgan Stanley—Is It Time to Buy?
• How to Use High Beta Stocks to Maximize Your Investing Profits
• 4 Quirky ETFs With Big Potential for Impressive Gains